GlaxoSmithKline Bill Positions
MapLight's report on GlaxoSmithKline details GlaxoSmithKline's support for or opposition to bills in Congress. MapLight has recorded 33 bill positions taken by GlaxoSmithKline since January 1, 2007. These bills relate to topics including Government Operations and Politics, Health, Budget, Spending, and Taxes, Intellectual Property, Business and Commerce, and 41 other topics.
Support and opposition information is based on public documents found by MapLight, including congressional testimony, news reports, and company statements. These documents are included with the report.
Scope:
This report provides, for each of the 33 bills GlaxoSmithKline has taken a position on, the following information:
* Bill name, number, and sponsor.
* Bill summary and status (i.e. whether the bill is in committee, has become law, etc.).
* GlaxoSmithKline's position (support or opposition).
* Date GlaxoSmithKline's position was taken and date it was recorded by MapLight.
* Source document for the support or opposition stance.
Source documents:
Source documents for GlaxoSmithKline's support or opposition stance are authored by:
* Invest in America's Future; Company, Organization Letter to Congress on the R&D Tax Credit (7 pages)
* Press Releases; Coalition Supports Patent Reform Legislation Adopted in Senate Judiciary Committee (1 pages)
* Press Releases; Coalition Supports Patent Reform Legislation Adopted in Senate Judiciary Committee (1 pages)
* Invest in America's Future; Company, Organization Letter to Congress on the R&D Tax Credit (7 pages)
* Patents Matter; America Invents Act Boosts Innovation & Jobs, Strengthens Patent System (1 pages)
* Patents Matter; America Invents Act Boosts Innovation & Jobs, Strengthens Patent System (1 pages)
* R&D Credit Coalition; R&D Credit Coalition Applauds House Introduction of Bipartisan Bill to Spur Innovation, Create Jobs & Boost GDP (5 pages)
* Robert P. Casey, Jr. United States Senator for Pennsylvania; Casey Introduces Bipartisan Bill to Help Develop Treatments for Rare Diseases (3 pages)
* Patents Matter; Coalition Statement (2 pages)
* And others.
Reasons to buy:
* Gauge future potential of GlaxoSmithKline based on whether a bill they support or oppose advances or is defeated in Congress.
* Evaluate the political activity of GlaxoSmithKline, including legislation of interest.
* Understand the reasoning behind GlaxoSmithKline's positions on legislation through content of source documents.
* Learn of other organizations that have taken the same position as GlaxoSmithKline on a bill (other signers).
* Learn of legislation which affects the financial prospects of GlaxoSmithKline.
* Learn whether bills GlaxoSmithKline has supported or opposed have been enacted, defeated, or are still pending.
Topics of legislation:
The bills GlaxoSmithKline has taken a position on cover the following topics: Government Affairs (22), Business & Labor (19), Health & Welfare (17), Science, Technology, Communications, and Infrastructure (16), Budget & Economy (15), Legal Affairs (14), Culture and Social Issues (9), Defense, National Security and Foreign Policy (9), Natural Resources (6), Education (1). The report is 148 pages long, including 36 source documents.